Search for a trial

A phase I, randomized, placebo-controlled, double blind, first time in human, escalating single-dose study to evaluate the safety, tolerability pharmacokinetics and pharmacodynamics of Neu-P12 in healthy male volunteers

Primary objectiveTo assess safety and tolerability of Neu-P12 in four different single doses of the drug. Secondary objectiveTo compare the pharmacokinetics, pharmacodynamics, safety, and tolerability of different single doses of Neu-P12.

International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 months

Primary objective:To assess the efficacy of PXT3003 compared to Placebo on the disability measured by the ONLS score in CMT1A patients treated for 15 months.Secondary objectives:- To assess the efficacy of PXT3003 compared to Placebo on clinical and…

Relation between human islet amyloid polypeptide (hIAPP) and pain phenotype in chronic idiopathic axonal polyneuropathy (CIAP) and diabetic polyneuropathy (DPN) patients

The primary objective of phase 1 is to validate a new ELISA measurement that can determine hIAPP oligomers reliably in plasma, and of phase 2 is to correlate pathogenic oligomer hIAPP (in plasma and skin) with pain and sensory disturbances in CIAP…